Expression of the potential therapeutic target claudin-18.2 is frequently decreased in gastric cancer: results from a large Caucasian cohort study
Sign Up to like & getrecommendations! Published in 2019 at "Virchows Archiv"
DOI: 10.1007/s00428-019-02624-7
Abstract: Gastric cancer (GC) is frequently diagnosed and treated in advanced tumour stages with poor prognosis. Recent studies have identified isoform 2 of the tight junction protein claudin-18 (CLDN18.2) as a promising target in GC therapy.… read more here.
Keywords: expression cldn18; gastric cancer; target; cohort ... See more keywords
Claudin-18.2 immunohistochemical evaluation in pancreatic cancer specimens: review and recommendations for routine testing and scoring
Sign Up to like & getrecommendations! Published in 2025 at "Virchows Archiv"
DOI: 10.1007/s00428-025-04222-2
Abstract: The evaluation of claudin-18 (CLDN18) by immunohistochemistry (IHC) has already entered routine diagnostic activity as a predictive biomarker for patients with gastric and gastroesophageal junction adenocarcinomas. Of note, the CLDN18 gene encodes for 2 isoforms,… read more here.
Keywords: testing scoring; cldn18; claudin immunohistochemical; evaluation pancreatic ... See more keywords
Global prevalence of claudin 18 isoform 2 in tumors of patients with locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma
Sign Up to like & getrecommendations! Published in 2024 at "Gastric Cancer"
DOI: 10.1007/s10120-024-01518-1
Abstract: Limited data exist for global prevalence of claudin 18 isoform 2 (CLDN18.2) positivity and association of CLDN18.2 status with clinical and tumor characteristics in patients with locally advanced (LA) unresectable or metastatic gastric or gastroesophageal… read more here.
Keywords: cldn18; adenocarcinoma; cldn18 positivity; tumor ... See more keywords
Preparation of Radiolabeled Zolbetuximab Targeting CLDN18.2 and Its Preliminary Evaluation for Potential Clinical Applications.
Sign Up to like & getrecommendations! Published in 2024 at "Molecular pharmaceutics"
DOI: 10.1021/acs.molpharmaceut.4c00122
Abstract: Claudin18.2 (CLDN18.2), due to its high expression in various gastric cancer tissues, is considered an optimal target for antitumor drug molecules. In this study, we obtained the labeled compounds of [125I]I-zolbetuximab using the Iodogen method.… read more here.
Keywords: cldn18; zolbetuximab; zolbetuximab targeting; preparation radiolabeled ... See more keywords
CD64+ fibroblast-targeted vilanterol and a STING agonist augment CLDN18.2 BiTEs efficacy against pancreatic cancer by reducing desmoplasia and enriching stem-like CD8+ T cells
Sign Up to like & getrecommendations! Published in 2024 at "Gut"
DOI: 10.1136/gutjnl-2024-332371
Abstract: Objective The objective of this study is to improve the efficacy of CLDN18.2/CD3 bispecific T-cell engagers (BiTEs) as a promising immunotherapy against pancreatic ductal adenocarcinoma (PDAC). Design Humanised hCD34+/hCD3e+, Trp53R172HKrasG12DPdx1-Cre (KPC), pancreas-specific Cldn18.2 knockout (KO),… read more here.
Keywords: cldn18; cd8 cells; stem like; sting agonist ... See more keywords
Dynamic modulation of claudin18.2 expression and remodeling of the tumor microenvironment in gastric cancer during chemo-immunotherapy
Sign Up to like & getrecommendations! Published in 2025 at "Journal for Immunotherapy of Cancer"
DOI: 10.1136/jitc-2025-012683
Abstract: Background Claudin 18.2 (CLDN18.2) is a tight junction protein retained in malignant transformation of gastric cancer (GC) and is a promising therapeutic target. Despite the clinical benefit of zolbetuximab in CLDN18.2-positive tumors, the dynamic expression… read more here.
Keywords: cldn18; gastric cancer; cldn18 positive; positive tumors ... See more keywords
Preclinical development and a case report of a nanobody-based CLDN18.2 CAR-T IMC002 with reduced on-target off-tumor toxicity.
Sign Up to like & getrecommendations! Published in 2025 at "Molecular cancer therapeutics"
DOI: 10.1158/1535-7163.mct-25-0171
Abstract: Claudin18.2 (CLDN18.2)-targeted chimeric antigen receptor T (CAR-T) cell therapy has shown promising antitumor activity in gastrointestinal cancers. However, limited persistence in solid tumors and on-target off-tumor (OTOT) toxicity remain significant challenges. Here, we report on… read more here.
Keywords: cldn18; imc002; toxicity; car ... See more keywords
Abstract B016: Updated Safety, Efficacy and Biomarker Analysis from the Phase I Study of Givastomig, a Novel Claudin 18.2/4-1BB Bispecific Antibody, in Claudin 18.2 Positive Advanced Gastroesophageal Carcinoma (GEC)
Sign Up to like & getrecommendations! Published in 2025 at "Molecular Cancer Therapeutics"
DOI: 10.1158/1535-7163.targ-25-b016
Abstract: Claudin 18.2 (CLDN18.2) is a validated target in GEC, but novel approaches are needed. Givastomig/ABL111 (giva) is a first-in-class, bispecific antibody targeting tumoral CLDN18.2 and 4-1BB on adjacent T cells, preferentially activating T cells in… read more here.
Keywords: cldn18; bispecific antibody; updated safety; gec ... See more keywords
Abstract 5386: In situ detection of CLDN18.2 RNA in circulating tumor cells in gastrointestinal cancer
Sign Up to like & getrecommendations! Published in 2020 at "Clinical Trials"
DOI: 10.1158/1538-7445.am2020-5386
Abstract: Objective: Recent clinical trials considered Claudin18 splice variants 2 (CLDN18.2) as the promising potential target for gastrointestinal(GI) cancer treatment. CLDN18.2 specifically express in normal stomach and gastric cancer, while ectopic activation can also be found… read more here.
Keywords: cldn18 rna; cldn18; cancer; ctcs ... See more keywords
Abstract 2962: ASP2138, a novel 2+1 format, claudin 18.2 x CD3 bispecific antibody, demonstrates selectivity and activity in preclinical cancer models
Sign Up to like & getrecommendations! Published in 2023 at "Cancer Research"
DOI: 10.1158/1538-7445.am2023-2962
Abstract: Claudin 18.2 (CLDN18.2) is a member of the claudin family of proteins that are involved in the formation of tight junctions in epithelia and endothelia. In normal tissue, CLDN18.2 is expressed exclusively on gastric epithelial… read more here.
Keywords: cd3; cell; asp2138; cldn18 ... See more keywords
Abstract CT081: A phase 1/2 study investigating the safety and efficacy of autologous TAC T cells in subjects with unresectable, locally advanced, or metastatic claudin 18.2+ solid tumors
Sign Up to like & getrecommendations! Published in 2024 at "Cancer Research"
DOI: 10.1158/1538-7445.am2024-ct081
Abstract: Background: CLDN18.2 is a tight junction protein found in differentiated gastric epithelial cells, which can become abnormally or ectopically expressed in a number of solid tumor indications. This exposure profile illustrates the potential of CLDN18.2… read more here.
Keywords: cldn18; tac01 cldn18; tac; efficacy ... See more keywords